



ASX ANNOUNCEMENT

Shareholder Webinar

Online presentation of company update and 1H FY 2023 result roadshow

MELBOURNE, Australia (2 March 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to invite shareholders and other interested parties to a Shareholder Webinar hosted by CEO Doug Ward.

In the webinar, CEO Doug Ward will provide an update on the commercial operations of Lumos Diagnostics since his appointment, and an overview of the achievements and financial result for H1 FY2023. Mr Ward will be providing this update at meetings with shareholders and investors during his visit to Australia in the week commencing 6 March 2023.

The webinar will be held on **Monday 6 March 2023 at 11.00am AEDT**.

For the Q&A session, investors are invited to send questions prior to the webinar to:

matt@nwrcommunications.com.au

Register for the webinar at the link below:

https://us02web.zoom.us/webinar/register/WN_yvV2Rm0mR1Cr8Uq-hRH1qQ

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those who would prefer to join by phone. A recording will be available at the above link shortly after the conclusion of the live session.

This announcement has been approved by the Lumos Disclosure Committee.

-Ends-

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions.

Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598